Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
Main Authors: | David Parker, Marc-Antoine Belaud-Rotureau |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2014-12-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | http://www.la-press.com/micro-cost-analysis-of-alk-rearrangement-testing-by-fish-to-determine--article-a4554 |
Similar Items
-
Micro-cost Analysis of Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
by: David Parker, et al.
Published: (2014-01-01) -
Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
by: F. Guisier, et al.
Published: (2020-01-01) -
Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
by: Shun Lu, et al.
Published: (2018-01-01) -
Fatal Haemoptysis Associated with Dramatic Response to Crizotinib in an ALK-Rearranged Lung Adenocarcinoma
by: Elodie Mussat, et al.
Published: (2016-03-01) -
NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
by: Cao Q, et al.
Published: (2019-02-01)